Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy

被引:48
|
作者
Pereira, Vanessa Goncalves
Martins, Ana Maria
Micheletti, Cecilia
D'Almeida, Vania
机构
[1] Univ Fed Sao Paulo, Dept Pediat, Inst Genet & Inborn Errors Metab, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Hlth Sci, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
mucopolysaccharidosis type I; alpha-L-iduronidase; IDUA gene; enzyme replacement therapy; oxidative stress;
D O I
10.1016/j.cca.2007.09.008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Mucopolysaccharidosis type I (NIPS 1) patients present a wide range of clinical manifestations, which could be due to the high molecular heterogeneity of the IDUA gene and to pathological events besides the enzyme deficiency. The aim of this study was to identify the most common MPS I causing mutations and to evaluate some oxidative stress markers in Brazilian patients. Methods: 3 common mutations in the IDUA gene were searched in 11 MPS I patients by PCR-RFLP. Activities of antioxidant enzymes catalase and superoxide dismutase, and levels of total glutathione and thiobarbituric acid reactive substances were evaluated by spectrophotometric and colorimetric methods, during different periods of enzyme replacement therapy. Results: The most common mutations were P533R and W402X, with allelic frequencies of 33.33% and 27.8% respectively. MPS I patients presented high levels of lipid peroxidation and enzyme replacement therapy led to an increase of catalase and a decrease of superoxide dismutase activities. Conclusions: P533R and W402X accounted for more than 60% of the alleles, but no genotype-phenotype correlation could be established. The alterations in antioxidant enzyme activities suggest that oxidative stress may be an important event among MPS I patients, which could contribute to the physiopathology of the disease. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 79
页数:5
相关论文
共 50 条
  • [1] Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy
    Karageorgeos, L
    Harmatz, P
    Simon, J
    Pollard, A
    Clements, PR
    Brooks, DA
    Hopwood, JJ
    HUMAN MUTATION, 2004, 23 (03) : 229 - 233
  • [2] Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy
    Filippon, Leticia
    Vanzin, Camila S.
    Biancini, Giovana B.
    Pereira, Izabela N.
    Manfredini, Vanusa
    Sitta, Angela
    Peralba, Maria do Carmo R.
    Schwartz, Ida V. D.
    Giugliani, Roberto
    Vargas, Carmen R.
    MOLECULAR GENETICS AND METABOLISM, 2011, 103 (02) : 121 - 127
  • [3] Enzyme replacement therapy in mucopolysaccharidosis type I
    Miebach, E
    ACTA PAEDIATRICA, 2005, 94 : 58 - 60
  • [4] Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy
    Donida, Bruna
    Marchetti, Desiree P.
    Biancini, Giovana B.
    Deon, Marion
    Manini, Paula R.
    da Rosa, Helen T.
    Moura, Dinara J.
    Saffi, Jenifer
    Bender, Fernanda
    Burin, Maira G.
    Coitinho, Adriana S.
    Giugliani, Roberto
    Vargas, Carmen Regla
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (05): : 1012 - 1019
  • [5] Laronidase (Aldurazyme®):: enzyme replacement therapy for mucopolysaccharidosis type I
    Pastores, Gregory M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (07) : 1003 - 1009
  • [6] Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
    Dornelles, Alicia Dorneles
    Pinto, Louise Lapagesse de Camargo
    de Paula, Ana Carolina
    Steiner, Carlos Eduardo
    Lourenco, Charles Marques
    Kim, Chong Ae
    Gandelman Horovitz, Dafne Dain
    Ribeiro, Erlane Marques
    Valadares, Eugenia Ribeiro
    Goulart, Isabela
    Neves de Souza, Isabel C.
    da Costa Neri, Joao Ivanildo
    Santana-da-Silva, Luiz Carlos
    Silva, Luiz Roberto
    Ribeiro, Marcia
    de Oliveira Sobrinho, Ruy Pires
    Giugliani, Roberto
    Doederlein Schwartz, Ida Vanessa
    GENETICS AND MOLECULAR BIOLOGY, 2014, 37 (01) : 23 - 29
  • [7] Identification and molecular characterization of α-L-iduronidase mutations present in mucopolysaccharidosis Type I patients undergoing enzyme replacement therapy
    Yogalingam, G
    Guo, XH
    Muller, VJ
    Brooks, DA
    Clements, P
    Kakkis, ED
    Hopwood, JJ
    HUMAN MUTATION, 2004, 24 (03) : 199 - 207
  • [8] Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II
    Wraith, J. Edmond
    ACTA PAEDIATRICA, 2008, 97 : 76 - 78
  • [9] Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
    Jameson, Elisabeth
    Jones, Simon
    Remmington, Tracey
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [10] Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy
    Gonzalez, Esteban A.
    Visioli, Fernanda
    Pasqualim, Gabriela
    de Souza, Carolina F. M.
    Marinho, Diane R.
    Giugliani, Roberto
    Matte, Ursula
    Baldo, Guilherme
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 48 (03) : 334 - 342